Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) EBT (2016 - 2025)

Historic EBT for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $43.4 million.

  • Collegium Pharmaceutical's EBT rose 17879.33% to $43.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.9 million, marking a year-over-year decrease of 3683.88%. This contributed to the annual value of $98.6 million for FY2024, which is 3015.2% up from last year.
  • As of Q3 2025, Collegium Pharmaceutical's EBT stood at $43.4 million, which was up 17879.33% from $17.0 million recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's EBT registered a high of $46.7 million during Q4 2023, and its lowest value of -$38.9 million during Q4 2021.
  • In the last 5 years, Collegium Pharmaceutical's EBT had a median value of $15.5 million in 2021 and averaged $10.8 million.
  • Over the last 5 years, Collegium Pharmaceutical's EBT had its largest YoY gain of 333866.67% in 2021, and its largest YoY loss of 63533.46% in 2021.
  • Over the past 5 years, Collegium Pharmaceutical's EBT (Quarter) stood at -$38.9 million in 2021, then soared by 79.96% to -$7.8 million in 2022, then soared by 699.54% to $46.7 million in 2023, then plummeted by 63.03% to $17.3 million in 2024, then soared by 151.53% to $43.4 million in 2025.
  • Its EBT stands at $43.4 million for Q3 2025, versus $17.0 million for Q2 2025 and $3.1 million for Q1 2025.